Tonix, MGH announce partnership on phase 2 trial for binge eating disorder drug

Tonix Pharmaceuticals Holding Corp. and Massachusetts General Hospital have announced an agreement to evaluate TNX-1900 as a potential treatment for patients with binge eating disorder.

According to a press release, the investigator-initiated phase 2 clinical trial, which is expected to launch in the second half of 2022, will be a randomized, double-blind, placebo-controlled study of 60 patients diagnosed with both binge eating disorder and obesity.

Over the course of the 8-week study, TNX-1900 will be evaluated for efficacy and safety, and to determine whether it reduces frequency of bingeing and body weight in adults with binge eating disorder and obesity, as well as any underlying mechanisms.

“Binge eating disorder is a serious mental health condition associated with behavioral and metabolic morbidity for which there are few treatment options,” Seth Lederman, MD, CEO of Tonix, said in the release.

“We are hopeful that our proprietary intranasal dosage form will enhance its properties for use in the underserved population of patients suffering from binge eating disorder.”